Growing Portfolio As part of Nexelis, AIT Bioscience has expanded its offerings to include advanced bioanalytical LC/MS, ligand binding platforms, and electronic laboratory notebooks, positioning it as a comprehensive partner for pharmaceutical clients across various development stages.

Strategic Acquisitions Nexelis, the parent company of AIT Bioscience, continues to invest in GCLP-certified bioanalytical laboratories and acquisitions, demonstrating a strong commitment to expanding its analytical capabilities and market reach in clinical testing services.

Market Expansion With recent investments and acquisition activities, Nexelis (and by extension AIT Bioscience) is actively positioning itself for growth within the competitive bioanalytical space, creating opportunities to serve a diverse range of pharmaceutical and biotech clients.

Flexibility in Service Delivery The company's focus on small and large molecule testing, along with its electronic lab notebook technology, offers tailored, cost-effective workflows that can meet the evolving needs of biotech and pharma sponsors, inviting potential collaborations.

Financial Opportunity With an estimated revenue range of $10 million to $50 million and ongoing strategic growth efforts, AIT Bioscience presents a promising opportunity for partners seeking to expand their analytical service capacity in a competitive landscape.